Nature Medicine, Published online: 11 November 2024; doi:10.1038/s41591-024-03346-3
The I-SPY clinical trial platform was designed to accelerate clinical development of neoadjuvant treatments for early-stage breast cancer. Although it is not without limitations, it provides a model for future response-adapted clinical trials.
